INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 416m ago
HOUSE PTR16m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
Corporate insider
GR

Gray Nancy Ryan

DirectorCIK 0001714949

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 2
Max Insider Score51
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
836 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    LIGAND PHARMACEUTICALS INCDirector · Nov 12, 2025
5
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A
—
2,938 sh
Jun 5, 2026
Jun 9, 2026
traded Jun 5, 2026
+4d
SEC FORM 4

Evidence

26
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$222K
3,015 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

15
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
3,556 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

51
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$619K
3,015 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

26
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$235K
3,556 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

15
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
3,015 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

51
GR
Gray Nancy RyanDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$731K
3,556 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence